DANCR was reported to modulate PI3K-Akt pathway in osteosarcoma, β-catenin pathway in hepatocellular carcinoma, miR-634-RAB1A signaling pathway in glioma, androgen-AR signaling pathway in prostate cancer [31, 32, 38, 39]. Here, DANCR is linked to hepatocellular carcinoma.